Results 221 to 230 of about 55,731 (254)
Some of the next articles are maybe not open access.
Prescrire international, 2012
Sorafenib inhibits multiple kinases involved in angiogenesis and tumour growth. It is used for second-line treatment of advanced kidney cancer and some forms of liver cancer. A placebo-controlled trial in 80 patients with metastatic kidney cancer showed a statistically significant increase in muscle loss during sorafenib therapy.
openaire +1 more source
Sorafenib inhibits multiple kinases involved in angiogenesis and tumour growth. It is used for second-line treatment of advanced kidney cancer and some forms of liver cancer. A placebo-controlled trial in 80 patients with metastatic kidney cancer showed a statistically significant increase in muscle loss during sorafenib therapy.
openaire +1 more source
Muscle wasting: emerging pathways and potential drug targets
Trends in Pharmacological Sciences, 2023Aylin Domaniku +2 more
exaly
2016
Cachexia occurs commonly and is a significant cause of morbidity and up to 20% mortality in patients with cancer. Loss of muscle mass occurs as part of the cachexia wasting process and low muscle mass is a key element of the most recent consensus cachexia definition.
openaire +1 more source
Cachexia occurs commonly and is a significant cause of morbidity and up to 20% mortality in patients with cancer. Loss of muscle mass occurs as part of the cachexia wasting process and low muscle mass is a key element of the most recent consensus cachexia definition.
openaire +1 more source
Muscle wasting in disease: molecular mechanisms and promising therapies
Nature Reviews Drug Discovery, 2014Shenhav Cohen +2 more
exaly
Cytokine Signaling in Skeletal Muscle Wasting
Trends in Endocrinology and Metabolism, 2016Chun Liang, Yangxin Li, Yao-Hua Song
exaly
Muscle wasting in young patients with dilated cardiomyopathy
Journal of Cachexia, Sarcopenia and Muscle, 2017Marjan Hajahmadi +2 more
exaly